LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Chernyshov, Pavel V. (2011)
Publisher: Microbial Ecology in Health and Disease
Journal: Microbial Ecology in Health and Disease
Languages: English
Types: Article
Subjects:
Background and aim: A benefi cial role of probiotics, especially Lactobacillus rhamnosus, in children with atopic dermatitis (AD) has been reported. Their effects are primarily mediated through immune pathways, which need further investigation. This study aimed to investigate clinical and immunologic effects of probiotics in the treatment of children with AD. Methods: Thirty children with AD received probiotic Lacidofi l and 28 other children with AD received placebo, one capsule per day. All children used emollient Trixera. SCORAD, specifi c IgE, specifi c IgG4 to cow’s milk, CD45RA+, CD45RO+ and transitional CD45RA+RO+ CD4+ T cells were studied at day 1 and day 30. Results: Marked reduction of SCORAD in 63.3% of patients in the treatment group and in 32.1% in the placebo group was reported. The decline of SCORAD in patients who did not use topical steroids during the follow-up period was signifi cant in the treatment group (p < 0.01) and not signifi cant in the placebo group. After the treatment, levels of specifi c IgG4 to cow’s milk increased (p < 0.001) and percentages of transitional recently activated CD45RA+RO+ T cells decreased (p < 0.05). Conclusion: The use of probiotic Lacidofi l was associated with a higher number of patients who achieved marked clinical improvement and higher corticosteroid-sparing effect. Synergistic action of Lacidofi l and emollient Trixera was also confi rmed by signifi cant decline of transitional recently activated CD45RA+RO+ CD4+ T cells. We found significant increase of the levels of specific IgG4 to cow’s milk in the group of patients who received probiotic and emollient that was not reported in the treatment group and may be considered as a shift to tolerance.Key words: Emollients, T lymphocyte
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Gianetti A, Girolomoni G. Atopic dermatitis. In: Fritsch P, BurgdorfW, editors. EDF white book: skin diseases in Europe, 2nd edn. Berlin: ABW Wissenschaftsverlag GmbH. 2005. p. 69-71.
    • 2. Ellis C, Luger T. International Consensus Conference on Atopic Dermatitis II (ICCAD II): Chairman's introduction and overview. Br J Dermatol 2003;148(Suppl 63):1-2.
    • 3. Mohrenschlager M, Darsow U, Schnopp C, Ring J. Atopic eczema: what's new? J Eur Acad Dermatol Venereol 2006;20:503-13.
    • 4. Michail SK, Stolfi A, Johnson T, Onady GM. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2008;101:508-16.
    • 5. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93-103.
    • 6. Grüber C, Wendt M, Sulser C. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007;62:1270-6.
    • 7. Brouwer ML, Wolt-Plompen SA, Dubois AE, van der Heide S, Jansen DF, Hoijer MA, et al. No effects of probiotics in atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy 2006;36:899-906.
    • 8. Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2008; 122:788-94.
    • 9. Prescott SL, Dunstan JA, Hale J, Breckler L, Lehmann H, Weston S, et al. Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 2005;35:1557-64.
    • 10. Eyerich K, Huss-Marp J, Darsow U, Wollenberg A, Foerster S, Ring J, et al. Pollen grains induce a rapid and biphasic eczematous immune response in atopic eczema patients. Int Arch Allergy Immunol 2008;145:213-23.
    • 11. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001;107:535-41.
    • 12. Kanek R, Matsu T, Iwatsuki K, Motok Y, Oyama, Kaneko F. Biphasic cytokine expression by T cell clones from patients with atopic dermatitis with different incubation periods and strengths of stimuli. Fukushima J Med Sci 2001;47:51-62.
    • 13. Akdis CA, Akdis M, Simon HU, Blaser K. Regulation of allergic inflammation by skin-homing T cells in allergic eczema. Int Arch Allergy Immunol 1999;118:140-4.
    • 14. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Buck D, Terstappen LW. Control of lymphocyte recirculation in man. I. Differential regulation of the peripheral lymph node homing receptor L-selectin on T cells during the virgin to memory cell transition. J Immunol 1993;150:1105-21.
    • 15. Picker LJ, Treer JR, Ferguson-Darnell B, Collins PA, Bergstresser PR, Terstappen LW. Control of lymphocyte recirculation in man. II. Differential regulation of the cutaneous lymphocyte-associated antigen, a tissue-selective homing receptor for skin-homing T cells. J Immunol 1993;150:1122-36.
    • 16. Chernyshov PV. Transitional recently activated CD45RA RO CD4 T cells in children with atopic dermatitis. Eur J Immunol 2009;39(Suppl 1):S210-1.
    • 17. Kligler B, Hanaway P, Cohrssen A. Probiotics in children. Pediatr Clin North Am 2007;54:949-67.
    • 18. Pohjavuori E,Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol 2004;114:131-6.
    • 19. Sistek D, Kelly R, Wickens K, Stanley T, Fitzharris P, Crane J. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 2006;36: 629-33.
    • 20. Bruni FM, Piacentini GL, Peroni DG, Bodini A, Fasoli E, Boner AL. Cow's milk allergic children can present sensitisation to probiotics. Acta Paediatr 2009;98:321-3.
    • 21. Passeron T, Lacour JP, Fontas E, Ortonne JP. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy 2006;61:431-7.
    • 22. Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005;90:892-7.
    • 23. Viljanen M, Savilahti E, Haahtela T, JuntunenBackman K, Korpela R, Poussa T. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005;60: 494-500.
    • 24. Chernyshov PV. B7-2/CD28 costimulatory pathway in children with atopic dermatitis and its connection with IgE, intracellular IL-4 and IFN-gamma production by T cells during one month follow up. J Eur Acad Dermatol Venereol 2009;23:656-9.
    • 25. Hanifin GM, Rajka G. Diagnostic feature of atopic dermatitis. Acta Derm Venereol 1980;92(Suppl):44-7.
    • 26. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
    • 27. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol 2008;25:606-12.
    • 28. Grimalt R, Mengeaud V, Cambazard F; Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007;214:61-7.
    • 29. Noh G, Ahn HS, Cho NY, Lee S, Oh JW. The clinical significance of food specific IgE/IgG4 in food specific atopic dermatitis. Pediatr Allergy Immunol 2007;18:63-70.
    • 30. Stapel SO, Asero R, Ballmer-Weber BK, Knol EF, Strobel S, Vieths S, et al. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008;63:793-6.
    • 31. Tomicˇic´ S, Norrman G, Fälth-Magnusson K, Jenmalm MC, Devenney I, Böttcher MF. High levels of IgG(4) antibodies to foods during infancy are associated with tolerance to corresponding foods later in life. Pediatr Allergy Immunol 2009;20:35-41.
    • 32. Ruiter B, Knol EF, van Neerven RJ, Garssen J, BruijnzeelKoomen CA, Knulst AC, et al. Maintenance of tolerance to cow's milk in atopic individuals is characterized by high levels of specific immunoglobulin G4. Clin Exp Allergy 2007;37:1103-10.
    • 33. Loden M. The clinical benefit of moisturizers. J Eur Acad Dermatol Venereol 2005;19:672-8.
    • 34. Reid G. Safety of lactobacillus strains as probiotic agents. Clin Infect Dis 2002;35:349-50.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from